Here are 1-3 brief analogies for Aspen Neuroscience:

• Like CRISPR Therapeutics or Bluebird Bio, but focusing on personalized stem cell treatments for Parkinson's disease.
• The Vertex Pharmaceuticals of Parkinson's, developing highly specialized, personalized cell therapies for the neurological disorder.

• ANPD001: A personalized, autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron replacement therapy being developed for Parkinson's disease.

• Fujifilm Holdings Corporation (FUJIY)
• Lonza Group Ltd. (LONN)

Damien McDevitt, Ph.D. President and Chief Executive Officer

A distinguished leader in the biotech and pharmaceutical industry sectors, Damien McDevitt is recognized for his vision, strategic planning, and corporate leadership with a career spanning more than 30 years. Prior to Aspen Neuroscience, he served as CEO of Akcea Therapeutics, Inc., a rare diseases company, which was acquired by Ionis Pharmaceuticals in 2020. He also held senior executive roles at Ionis Pharmaceuticals, Acadia Pharmaceuticals, and GlaxoSmithKline Pharmaceuticals. Dr. McDevitt earned his B.A. and Ph.D. at Trinity College Dublin, Ireland.

Dalen Meeter, CPA, MBA Chief Financial Officer

Dalen Meeter brings more than two decades of finance and accounting experience to his role at Aspen Neuroscience. Prior to Aspen, he most recently served as CFO of Singular Genomics. He guided Singular's finance transformation from a private, development-stage startup to a publicly traded, commercial-stage company, and then led as CFO of the public entity. Before joining Singular, Mr. Meeter spent many years in Finance leadership at Illumina, as well as in auditing during his time at KPMG. He also held leadership positions at Websense, Inc., and Captiva Software. A certified public accountant (CPA), he earned his undergraduate degree from the University of California, Santa Barbara, and his MBA from the University of Southern California's Marshall School of Business.

Andrés Bratt-Leal, Ph.D. Co-Founder and Senior Vice President, Research & Development

Andrés Bratt-Leal is the Co-Founder and leads the research and development at Aspen Neuroscience. He served as a post-doctoral fellow in Jeanne Loring's lab where he helped develop the core technology producing dopaminergic neurons from iPSCs that formed the basis for the creation of Aspen. Dr. Bratt-Leal also served as Senior Science Advisor and Director of Research and Development at Summit for Stem Cell Foundation, during which he led a team on the pre-clinical development of an autologous cell-based cell therapy for Parkinson's disease. He obtained his Ph.D.

Xiaokui Zhang, Ph.D. Chief Scientific Officer

As Chief Scientific Officer, Xiaokui Zhang, Ph.D. leads the company's current scientific programs, as well as future platform and pipeline investments for the autologous iPSC platform company. Before joining Aspen, Dr. Zhang served as the Executive Vice President and Chief Scientific Officer.

Revati Shreeniwas, M.D., FCCP Chief Medical Officer

Revati Shreeniwas, M.D., FCCP was appointed Chief Medical Officer in January 2026. She brings more than 20 years of experience in global clinical development, with leadership across over 40 clinical trials and multiple registrational programs, where she has advanced assets from early stage/IND through global approvals. Her experience spans neurology and neurodegeneration in the CNS arena and includes contribution to the approval and commercialization of therapies such as RYTARY® (Parkinson's disease), SUNOSI®, Esbriet®, and TRACLEER®. Prior to Aspen, Dr. Shreeniwas served in senior clinical roles at Cystetic Medicines, Excision BioTherapeutics, Bright Minds Biosciences, and Soleno Therapeutics, among others. She received her medical education from Armed Forces Medical College in Pune, India, and held faculty appointments at Columbia University and Stanford University before working in the biopharma industry.

The key risks to Aspen Neuroscience (ASPE) are primarily related to its financial viability, the inherent challenges of clinical development, and the complexities of manufacturing and commercialization for its personalized cell therapies.

1. Need for Substantial Additional Capital and Going Concern Risk: Aspen Neuroscience has explicitly stated that its current cash, cash equivalents, and marketable securities are insufficient to fund its operations for another year, leading to "substantial doubt" about its ability to continue as a going concern. The company will require significant additional capital to finance its operations and advance its clinical pipeline, especially given that research and development constitute over 70% of its operating expenses.
2. Clinical Development and Regulatory Approval Risks: As a clinical-stage biotechnology company, Aspen Neuroscience's success is highly dependent on the successful completion of clinical trials and subsequent regulatory approvals for its product candidates. The lead candidate, sasineprocel (ANPD001), is currently in Phase 1/2a trials, with Phase 3 anticipated to begin dosing in the second half of 2027. There is no assurance that the promising early-stage results will be replicated in larger, later-stage studies. Furthermore, while the therapy has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, these designations do not guarantee a faster development process, expedited regulatory review, or a higher likelihood of eventual approval. Developing therapies for neurodegenerative diseases like Parkinson's is considered "extremely challenging" due to the limited understanding of disease mechanisms and the heterogeneity of pathologies.
3. Manufacturing and Commercialization Challenges of Personalized Cell Therapies: Aspen Neuroscience's approach involves autologous (patient-derived) cell therapies, which are inherently complex, expensive, and difficult to manufacture. The production process can take approximately four months, from obtaining a skin sample to implanting the cells. Scaling such personalized treatments into routine medical care will necessitate a "massive industrial footprint," and securing coverage from national healthcare systems and insurers for these individualized therapies presents a significant hurdle. While the company leverages automation, robotics, and AI to enhance efficiency and scalability, the fundamental challenges associated with the complexity and cost of personalized cell therapy manufacturing and broader market adoption remain.

Aspen Neuroscience (ASPE) is a clinical-stage biotechnology company focused on developing autologous induced pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases, with an initial emphasis on Parkinson's disease. Its lead product candidate is ANPD001 (sasineprocel), an investigational autologous iPSC-based cell therapy for Parkinson's disease.

The addressable market for technologies related to Aspen Neuroscience's focus, specifically the global induced pluripotent stem cells (iPSC) market, is substantial. This market, which includes applications in regenerative medicine, disease modeling, and drug discovery, was valued at USD 2.51 billion in 2026 and is projected to reach USD 5.44 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 10.14% from 2026 to 2034.

North America is a significant region within this market, accounting for 38.1% of the global iPSC market share in 2023. The U.S. alone is expected to contribute approximately 32% of the North American market.

A substantial portion of iPSC research and development is directly relevant to Aspen Neuroscience's core focus. Approximately 60% of active clinical trials involving iPSCs target neurological conditions such as Parkinson's disease. Furthermore, neurons are identified as the fastest-growing derived cell type within the iPSC market, driven by research demand for Parkinson's disease. The application of iPSCs in regenerative medicine is also experiencing rapid growth, with a CAGR of 12.33%.

Aspen Neuroscience (ASPE) is a clinical-stage biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD). The company's lead product candidate is sasineprocel (ANPD001). As the company is in its clinical development phase and recently filed for an IPO, its future revenue growth will be driven by the successful advancement and potential commercialization of its therapeutic pipeline and strategic initiatives.

Here are 3-5 expected drivers of future revenue growth for Aspen Neuroscience over the next 2-3 years:

1. Advancement and Commercialization of Sasineprocel for Sporadic Parkinson's Disease: The primary driver of future revenue growth is the successful progression of sasineprocel (ANPD001), their lead product candidate, through clinical trials, regulatory approval, and eventual commercial launch for sporadic Parkinson's disease. Sasineprocel is currently in Phase 1/2a clinical trials (ASPIRO trial), with plans to initiate a Phase 3 trial in the second half of 2027. The therapy has received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, which could expedite its development and review process.
2. Expansion of Sasineprocel into Genetic Parkinson's Disease and Broader PD Patient Populations: Aspen Neuroscience aims to maximize the therapeutic potential of sasineprocel by expanding its development into genetic forms of Parkinson's disease and other relevant patient populations. This expansion would broaden the potential market for sasineprocel, driving further revenue growth upon successful development and approval.
3. Development of New Product Candidates for Other Central Nervous System (CNS) Diseases: Beyond Parkinson's disease, Aspen Neuroscience is actively investigating additional candidates for other neurodegenerative diseases of the Central Nervous System. The company expects to initiate Investigational New Drug (IND)-enabling studies in the second half of 2027 for targeted genome editing approaches to address disease-associated genetic variants, indicating a pipeline expansion strategy that could lead to new revenue streams in the future.
4. Scalable and Automated Manufacturing Capabilities: The company has completed the construction of its GMP manufacturing facility in San Diego and is preparing it for qualification to support late-stage pivotal manufacturing and commercial readiness. Establishing a robust, scalable, and automated autologous cell manufacturing process is critical for producing therapies efficiently and cost-effectively, which will be a significant enabler for commercial-scale revenue generation once products are approved.
5. Strategic Collaborations and Partnerships: Aspen Neuroscience's business model includes the potential for revenue generation through partnerships and licensing agreements. The company's stated strategy involves opportunistically engaging in strategic collaborations, which could provide non-dilutive funding, access to new markets, and accelerate development and commercialization efforts, thereby contributing to future revenue growth through upfront payments, milestone achievements, and royalties.

Inbound Investments

• Aspen Neuroscience secured $147.5 million in Series B financing in 2022.
• The company closed a $115 million Series C financing round in November 2025.
• Total capital raised by the company exceeds $340 million, which includes an $8 million grant from the California Institute for Regenerative Medicine (CIRM).

Capital Expenditures

• In October 2024, Aspen Neuroscience expanded its San Diego presence with a new 22,000 square foot facility for GMP manufacturing.
• In January 2025, the company advanced plans for automating the production of ANPD001 and expanding autologous manufacturing capacity at its San Diego GMP facility.
• The proceeds from the November 2025 Series C financing are intended to scale manufacturing capabilities to meet both clinical and future commercial demand.